Quell Therapeutics’ Post

The challenge of enhancing the effectiveness and durability of engineered lymphocyte therapies is one of the key issues in the field of #lymphocyte engineering and cell therapy. The topic will be discussed in detail by top experts – Michel Sadelain, Univ.-Prof. Dr. med. Marion Subklewe and Jennifer Brogdon during the 1st session of #ICLE2025 – “Real-world experience, novel clinical approaches and combination therapies.” The session will aim to explore the potential synergy between engineered lymphocytes and other treatment modalities. Dive into the program to find out what else to expect: https://bit.ly/4bK8Gm2 #lymphocytes #lymphocytesengineering #CARTcells

Interested in learning more about Orca Bio’s investigational high-precision cell therapies? We partnered with The EBMT on a video that highlights the significant unmet need that exists for patients with #bloodcancer today, Orca Bio’s unique approach, and the potential for our investigational products to change the treatment paradigm. You can check out the video here: https://bit.ly/3Jku5GE #EBMT24 #bloodcancer #AML #oncology #leukemia

We’re 🤯 by the latest clinical trial research from Oncologie | UNIL-CHUV! Read our blog to see how they used #singlecell technologies to characterize the tumor-immune features that could be the key to successful adoptive cell therapy in metastatic #melanoma.

Discover how to engineer and analyze CAR-T cell signaling and activation using cutting-edge tools in our upcoming webinar. Learn from experts about innovative non-viral editing and analytical platforms that enhance CAR-T cell therapy efficiency. #CARTTherapy #GeneEditing #CancerResearch https://lnkd.in/gaQq5EVi

🏥 Is there a link between transplant center volume and GVHD outcomes? 📑 A new study published in the ASTCT's Transplantation and Cellular Therapy journal addressed the question. ➡️ Learn more: https://buff.ly/3uhS85m

⏰ Save The Date - 27th June ⏰ Join our upcoming webinar featuring a panel discussion on methods of streamlining the CAR-T workflow. As CAR-T cell therapy continues to advance it's important to address the challenges that come with it. One key issue is the manufacturing process, which can be costly and time-consuming. That's why efforts to create a more efficient CAR-T cell therapy manufacturing process are crucial. Join this webinar to learn more about the analytical tools that are contributing to these advancements! #celltherapy #CART

Carcinomas account for ~90% of cancers. This is why the recent FDA approval of TIL therapy is changing the field of cell therapy. In this podcast, Jason Bock talks with Daniel Levine about this achievement and what is on the horizon with the brilliant next generation TILs in development and in the clinic. #biotech #celltherapy #TILtherapy #endcancer https://lnkd.in/et-A5hUe

🔍 Join our upcoming webinar to explore the latest advancements in CAR-T cell signaling and activation. Gain insights from leading experts on innovative non-viral editing 🧬 and analytical platforms that are revolutionizing the efficiency of CAR-T cell therapy. 🌟

Our highly anticipated cell therapy webinar is just one week away, so secure your spot before it's too late ⏳ https://ter.li/9bwzoc Get ready to explore how allogeneic cell therapies are making waves with scalable and innovative alternatives to traditional autologous treatments. Here’s a sneak peek: 💸 Total deal value involving allogeneic cell therapies in 2023 was $981 million, but this year we’ve already surpassed that investment! 🔬 130 allogeneic trials have their end dates this year, providing a wealth of new data and insights. 🧪 Over 440 allogeneic trials are currently recruiting participants. Find out more about these promising developments. Our expert panel will dive deep into these exciting advancements. Don’t miss the chance to stay ahead of the curve and unlock the potential of cutting-edge allogeneic solutions in oncology and beyond. #CellTherapy #Allogeneic #AllogeneicTherapies #MarketInsights Hanson Wade Intelligence

CAR-T cell therapy challenges and their mitigation strategies . CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments (Journal of transnational Medicine )